Stamford, CT -- (SBWIRE) -- 12/27/2013 -- OTC Stock Picks is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our penny stock newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), OCZ Technology Group Inc. (NASDAQ:OCZ), Hemispherx BioPharma, Inc (NYSEMKT:HEB), Supernus Pharmaceuticals Inc (NASDAQ:SUPN)
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) opened the session at $12.20, trading in a range of $11.66 - $12.78. The stock showed a negative performance of -21.27% in the last trading session and closed at $11.81. The stock traded on a volume of 2.31 million shares and the average volume of the stock remained 250,312 shares. Oramed Pharmaceuticals, Inc., a development stage pharmaceutical company, is engaged in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company?s product portfolio includes ORMD0801, an oral insulin capsule that is in Phase II clinical trials for the treatment of diabetes; and ORMD0901, an analog for GLP-1 gastrointestinal hormone, which is in pre-clinical trials. Its portfolio of product candidates is based on intellectual property that allows for the protection of proteins and polypeptides in the stomach, and for their absorption through the gastrointestinal wall. T
Has ORMP Found The Bottom and Ready To Move Up? Find Out Here
OCZ Technology Group Inc. (NASDAQ:OCZ) traded 5.56 million shares in the last business day while the average volume of the stock remained 6.98 million shares. The stock showed a negative movement of -15.25% to end at $0.0500. The 52 week range of the stock remained $0.05 - $0.06. OCZ Technology Group, Inc. designs, manufactures, and distributes solid state drives (SSDs) and computer components primarily in the United States, Germany, the Middle East, Africa, and European countries. The company specializes in high-speed memory in the enterprise and consumer SSD markets, a technology that competes with traditional rotating magnetic hard disk drives. It supports interfaces, including PCI express, serial attached SCSI, and serial ATA for personal computers, servers, data storage systems, and industrial equipments; and offers enterprise products comprise Deneva 2 SATA SSDs, Talos 2 SAS Series, and Z-Drive R4 PCIe flash-based cards.
Has OCZ Found The Bottom And Ready To Gain Momentum? Find Out Here
Hemispherx BioPharma, Inc (NYSEMKT:HEB) reported 1.17 million shares were exchanged during the last trade, while the average volume is about 1.66 million shares. The stock dropped -6.44% and finished the day at $0.231. The beta of the stock is recorded at 1.76. Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Its products include Ampligen, which is under clinical development for the treatment of Chronic Fatigue Syndrome, Hepatitis B, human immunodeficiency virus (HIV), renal cell carcinoma, and malignant melanoma
Why Should Investors Buy HEB After the Recent Fall? Just Go Here and Find Out
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) shares dropped, -5.13 percent from its previous close of $8.38 to close at $7.95. Traded with volume of 1.53 million shares in the prior session and the average volume of the stock remained 693,105 shares. Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine.
Will SUPN Get Buyers Even After The Recent Rally? Find Out Here
About OTC Stock Picks
The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.
OTC Stock Picks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.
Read full disclaimer at: http://otcstockpicks.net/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)